Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $3.6 million.

  • Biodesix's Accounts Payables rose 4257.0% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 4257.0%. This contributed to the annual value of $2.2 million for FY2024, which is 2509.39% down from last year.
  • Biodesix's Accounts Payables amounted to $3.6 million in Q3 2025, which was up 4257.0% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Accounts Payables peaked at $3.7 million during Q1 2021, and registered a low of $1.2 million during Q2 2021.
  • For the 5-year period, Biodesix's Accounts Payables averaged around $2.4 million, with its median value being $2.2 million (2024).
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 8145.92% in 2021, then surged by 10556.62% in 2024.
  • Over the past 5 years, Biodesix's Accounts Payables (Quarter) stood at $1.7 million in 2021, then grew by 1.38% to $1.7 million in 2022, then soared by 73.83% to $2.9 million in 2023, then fell by 25.09% to $2.2 million in 2024, then skyrocketed by 64.86% to $3.6 million in 2025.
  • Its Accounts Payables stands at $3.6 million for Q3 2025, versus $3.0 million for Q2 2025 and $2.9 million for Q1 2025.